Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Innovative solutions and a deep understanding of the market makes this a unique combination
Five seats reserved for Wards of COVID warriors in central MBBS admission
Subscribe To Our Newsletter & Stay Updated
